Abstract
Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 131-138 |
Number of pages | 8 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2013 |
Externally published | Yes |
Keywords
- Acute myeloid leukemia
- Decitabine
- Myelodysplastic syndromes
- Myelomonocytic leukemia
- Risk factors
- chronic
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research